Abstract:BackgroundCardio-protective effect of fibrate therapy is controversial and current research is to evaluate the effect of fenofibrate therapy on rats with hypertriglycemia.MethodsRats with hypertriglycemia were produced by 10% fructose administration (10 ml daily) for 4 weeks. After model has been successfully produced as reflected by increased triglyceride level, different doses of fenofibrate, namely low dose (50 mg/kg body weight) and high dose (100 mg/kg body weight), were orally prescribed for 2 weeks. At baseline, 4 weeks of fructose administration and 2 weeks of fenofibrate therapy, parameters of interest were evaluated and compared.ResultsAt baseline, no significant differences of parameter were observed between groups. After 4 weeks of fructose prescription, triglyceride level increased in company with high density lipoprotein cholesterol (HDL-C) and apoprotein A1 (ApoA1) decreased. C-reactive protein (CRP) and malondialdehyde (MDA) levels were also elevated. Endothelial function was impaired as reflected by reduced nitric oxide (NO) production and elevated serum asymmetric dimethylarginine (ADMA) level. All these changes were significant as compared to the control group (P < 0.05), suggesting that short-term of triglyceride elevation could potently initiate atherosclerosis. With 2 weeks of fenofibrate therapy, in comparison to un-treated group, triglyceride level was significantly reduced in parallel with HDL-C and ApoA1 elevation. Inflammation and oxidation were also profoundly ameliorated as reflected by CRP and MDA reduction. Notably, NO production was enhanced in company with serum ADMA level decrease. Overall, these improvements manifested in a dose-dependent manner, which was supported by multivariate regression analysis showing that after adjusted to other variables, the dose of fenofibrate therapy remained significantly associated with NO production and serum ADMA level, with OR of 1.042 (high-dose versus low-dose, 95% CI 1.028-1.055, P < 0.05).ConclusionsFenofibrate therapy not only could reduce triglyceride level but also confer pleiotropic effects in terms of endothelium-protection and amelioration of inflammation and oxidation in a dose-dependent manner.

Fenofibrate Inhibits Thrombogenic and Fibrinolytic Factors Expression in Cultured Adipocytes from Rabbits

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Fenofibrate Reduces Serum Retinol-Binding Protein-4 by Suppressing Its Expression in Adipose Tissue

Efficacy And Safety Of Fenofibrate As An Add-On In Patients With Elevated Triglyceride Despite Receiving Statin Treatment

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Fenofibrate Inhibits Tumor Necrosis Factor-Alpha-induced Expression of CD40 and Matrix Metalloproteinase in Human Vascular Endothelial Cells.

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Fenofibrate Increases Serum Vaspin by Upregulating Its Expression in Adipose Tissue.

Inhibition Effect of Fenofibrate on Vascular Remodeling after Coronary Artery Injury

Toxic effect of fenofibrate on gel entrapped primary rat hepatocytes

Role of fenofibrate in activation of farnesoid X receptor transcriptional activity

Induction of the Phospholipid Transfer Protein Gene Accounts for the High Density Lipoprotein Enlargement in Mice Treated with Fenofibrate*

[The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes]

Effect of Angiotensin-Converting Enzyme Inhibitor on Vascular Cell Adhesion Molecule-1 Expression in a Rabbit Model of Early Atherosclerosis

Fenofibrate Attenuates Hepatic Fibrosis by PPAR-Α and TGF-β1/Smad Signaling Pathway Via Modulating Autophagy and Oxidative Stress

Activation of PPAR Alpha by Fenofibrate Inhibits Apoptosis in Vascular Adventitial Fibroblasts Partly Through SIRT1-mediated Deacetylation of FoxO1.

Fenofibrate Exerts Protective Effects In Diabetic Retinopathy Via Inhibition Of The Angptl3 Pathway

Fenofibrate enhances lipid deposition via modulating PPAR, SREBP-1c, and gut microbiota in <i>ob/ob</i> mice fed a high-fat diet

Effect of Fibrate Treatment on Circulating Adipokine Levels: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Fenoﬁbrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling